ClinicalTrials.gg

Program

lerodalcibep

Also written as “Lerodalcibep”, “LIB003” and “lerodalcibep 300 mg Monthly SC”.

Its studies are mostly in Hypercholesterolemia · Hyperlipoproteinemia Type II · Cardiovascular Diseases · Myocardial Infarction · Homozygous Familial Hypercholesterolemia, led by 2 companies.

Furthest: phase 3, since Jul 22, 201914 company-led studies, 7 open or runningNext primary completion: Jul 31, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
LIB Therapeutics125 open or runningphase 3since Jul 22, 2019May 22, 2018Jul 31, 2028phase 3 · NCT07102511
Hasten Biopharmaceutical22 open or runningphase 3since Aug 21, 2024Jul 2, 2024none ahead

Also a collaborator on its studies: medpace-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 22, 2018First study: phase 2 study in LDL CholesterolNew to LIB TherapeuticsLIB Therapeutics · NCT03549260 · 81 enrolled · United States
  2. Feb 14, 2019Phase 2 study in HypercholesterolemiaLIB Therapeutics · NCT03847974 · 32 enrolled · United States
  3. Jul 22, 2019Phase 3 study in Homozygous Familial HypercholesterolemiaLIB Therapeutics · NCT04034485 · 65 enrolled · United States, India, Israel and more
  4. Mar 6, 20215 phase 3 studiesLIB Therapeutics · NCT04790513, NCT04798430, NCT04797104 and 2 more
  5. Aug 6, 2021Phase 3 study in HypercholesterolemiaLIB Therapeutics · NCT05004675 · 166 enrolled · France, Germany, Norway and more
  6. Jan 17, 2022Phase 3 study in HypercholesterolemiaLIB Therapeutics · NCT05234775 · 22 enrolled · United States
  7. Jul 2, 2024Hasten Biopharmaceutical's first study: phase 1 study in HypercholesterolemiaNew to Hasten BiopharmaceuticalHasten Biopharmaceutical · NCT06504043 · 30 planned · China
  8. Aug 21, 2024Phase 3 study in HypercholesterolemiaHasten Biopharmaceutical · NCT06568471 · 210 planned · China
  9. Jul 28, 2025Phase 3 study in HypercholesterolemiaLIB Therapeutics · NCT07102511 · 150 planned · United States, Israel, New Zealand and more
  10. Aug 16, 2026Phase 3 study in Heterozygous Familial Hypercholesterolemia (HeFH)LIB Therapeutics · NCT07775339 · 150 planned · India, Israel, New Zealand and more

Ahead

  1. Jul 31, 2028Primary completion: phase 3 study in HypercholesterolemiaLIB Therapeutics · NCT07102511
  2. Jul 31, 2031Primary completion: phase 3 study in Heterozygous Familial Hypercholesterolemia (HeFH)LIB Therapeutics · NCT07775339

TargetBeta

PCSK9 →read by rule
“Subtilisin/kexin type 9 inhibitor”ChEMBL 37, by rule

Other programs on PCSK9

ProgramCompanyFurthest phaseStudies
alirocumabruleSanofiphase 448
evolocumabruleAmgenphase 445
inclisiranruleNovartisphase 437
tafolecimabruleInnovent Biologicsphase 38
recaticimabruleJiangsu HengRui Medicinephase 37
QLC7401ruleQilu Pharmaceuticalphase 35
SAL003ruleShenzhen Salubris Pharmaceuticalsphase 33
VERVE-102Eli Lillyphase 22
DNV001rulehangzhou-dinovate-biotech-co-ltdphase 21
RBD7022ruleQilu Pharmaceuticalphase 12

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07775339Heterozygous Familial Hypercholesterolemia (HeFH) · India, Israel, New Zealand and more3Not yet recruitingLIB TherapeuticsJul 31, 2031150
NCT07102511Hypercholesterolemia · United States, Israel, New Zealand and more3By invitationLIB TherapeuticsJul 31, 2028150
NCT06568471Hypercholesterolemia · China3RecruitingHasten BiopharmaceuticalFeb 2026210
NCT06504043Hypercholesterolemia · China1By invitationHasten BiopharmaceuticalJan 8, 202530
NCT05234775Hypercholesterolemia · United States3CompletedLIB TherapeuticsJun 30, 202222
NCT05004675Hypercholesterolemia · France, Germany, Norway and more3CompletedLIB TherapeuticsMay 30, 2024166
NCT04806893Cardiovascular Diseases · United States, India, Israel3Active, not recruitingLIB TherapeuticsNov 15, 2023900
NCT04797247Cardiovascular Diseases · United States3Active, not recruitingLIB TherapeuticsNov 15, 2023900
NCT04797104Heterozygous Familial Hypercholesterolemia · United States, Israel, Norway and more3CompletedLIB TherapeuticsJul 30, 2023478
NCT04798430Hypercholesterolemia · United States, India, Israel and more3By invitationLIB TherapeuticsJul 30, 20252,000
NCT04790513Hypercholesterolemia · United States3CompletedLIB TherapeuticsSep 30, 2022204
NCT04034485Homozygous Familial Hypercholesterolemia · United States, India, Israel and more3CompletedLIB TherapeuticsSep 12, 202265
NCT03847974Hypercholesterolemia · United States2CompletedLIB TherapeuticsApr 7, 202032
NCT03549260LDL Cholesterol · United States2CompletedLIB TherapeuticsNov 9, 201881

How it is read

Names in the registry

  • “lerodalcibep”, 8 entries
  • “Lerodalcibep”, 2 entries
  • “LIB003”, 2 entries
  • “lerodalcibep 300 mg Monthly SC”, 1 entry
  • “HST101”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.